title: Subpressor dose of L-NAME unmasks hypertensive effect of chronic hyperinsulinemia.
abstract: We previously found that chronic exogenous hyperinsulinemia without sugar supplementation does not elevate blood pressure. This may be partially explained by the ability of insulin to release nitric oxide and cause vasodilatation. To test this hypothesis, we studied 4 groups of rats: 9 rats (body weight, 213+/-14 g) treated with a gradual increase of a sustained-release subcutaneous insulin pellet; 9 rats (body weight, 213+/-9 g) treated with N:(G)-nitro-L-arginine methyl ester (L-NAME) in drinking water 50 mg/L; 19 rats (body weight, 217+/-11 g) treated with the combination of L-NAME and insulin; and 9 control rats (body weight, 218+/-11 g). Blood pressure was followed weekly for 6 weeks, and then rats were studied in metabolic cages. Weight gain was not different during the 6 weeks. Renal function did not differ between the 4 groups, but 24-hour urinary nitrite/nitrate excretion was lower (P<0.02) in L-NAME-treated and higher in insulin-treated rats. Plasma insulin doubled (P<0.002) in the insulin-treated rats, but there was no hypoglycemia and, by week 6, fructosamine levels were 2.1+/-0.2, 2.1+/-0.2, 2.3+/-0.1, and 2.3+/-0.2 mmol/L in control rats and rats treated with L-NAME, insulin, and L-NAME plus insulin, respectively. Systolic blood pressure, which did not differ at baseline, at week 3 was 122+/-17, 118+/-17, and 118+/-24 mm Hg in the control, L-NAME, and insulin groups and 136+/-14 mm Hg (P<0.03) in the combination group. At week 6, systolic blood pressure was 128+/-14, 127+/-15, and 118+/-13 mm Hg in the control, L-NAME, and insulin groups, respectively, and 150+/-14 mm Hg (P<0.0005) in the combination group. In a subsequent experiment, L-arginine 2 g/L abrogated the effects of L-NAME and insulin combination. In conclusion, chronic exogenous hyperinsulinemia does not affect blood pressure but may cause hypertension when endothelial function is compromised.
authors.affiliation: Hypertension Unit, Department of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem. bursz@cc.huji.ac.il
authors.forename: M
authors.initials: M
authors.lastname: Bursztyn
authors.forename: J
authors.initials: J
authors.lastname: Mekler
authors.forename: E
authors.initials: E
authors.lastname: Peleg
authors.forename: J
authors.initials: J
authors.lastname: Bernheim
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006946:Hyperinsulinism / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D006973:Hypertension / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis*; D007328:Insulin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
chemical_list: D004343:Drug Implants; D004791:Enzyme Inhibitors; D007328:Insulin; D009569:Nitric Oxide; D019331:NG-Nitroarginine Methyl Ester